T H Grote
Overview
Explore the profile of T H Grote including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navari R, Reinhardt R, Gralla R, Kris M, Hesketh P, Khojasteh A, et al.
N Engl J Med
. 1999 Jan;
340(3):190-5.
PMID: 9917226
Background: The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be an...
2.
Whitmore J, Kris M, Hesketh P, Grote T, DUBOIS D, Cramer M, et al.
Support Care Cancer
. 1998 Oct;
6(5):473-8.
PMID: 9773466
Dolasetron mesilate is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting. For the majority of patients in intravenous dolasetron trials for chemotherapy-induced nausea and vomiting,...
3.
Kris M, Pendergrass K, Navari R, Grote T, Nelson A, Thomas V, et al.
J Clin Oncol
. 1997 May;
15(5):2135-8.
PMID: 9164228
Purpose: Dolasetron is a 5-HT3 antagonist antiemetic with active oral and intravenous formulations. The effects of this class are enhanced when combined with dexamethasone. This study tested the ability of...
4.
Rubenstein E, Gralla R, Hainsworth J, Hesketh P, Grote T, Modiano M, et al.
Cancer
. 1997 Mar;
79(6):1216-24.
PMID: 9070501
Background: This double blind parallel group study assessed the acute antiemetic efficacy of four oral doses of dolasetron mesylate in cancer patients receiving their first course of intravenous chemotherapy with...
5.
Grote T, Pineda L, Figlin R, Pendergrass K, Hesketh P, Karlan B, et al.
Cancer J Sci Am
. 1997 Jan;
3(1):45-51.
PMID: 9072308
Purpose: This double-blind, dose-response study was conducted to assess the safety and efficacy of four oral doses of dolasetron mesylate for preventing acute emesis in cancer patients receiving their first...
6.
Atkins J, Muss H, Case D, Brockschmidt J, Schnell F, ORourke M, et al.
Am J Clin Oncol
. 1991 Dec;
14(6):526-9.
PMID: 1957840
Thirty-two patients with metastatic carcinoma of the prostate refractory to endocrine therapy were entered on trial. No patient entered in the study had prior chemotherapy. Patients were treated with 5-fluorouracil...
7.
Grote T, Grosh W, List A, Wiley R, Cousar J, Johnson D
Am J Clin Oncol
. 1989 Apr;
12(2):93-100.
PMID: 2650529
Twenty patients with primary non-Hodgkin's lymphoma of the central nervous system (CNS) were seen at Vanderbilt and its affiliated hospitals between 1974 and 1986. Histologically, the most common subtypes were...
8.
Grote T, Macon W, Davis B, Greco F, Johnson D
Chest
. 1988 Feb;
93(2):370-5.
PMID: 2827965
Eleven cases of atypical carcinoid (AC) of the lung were identified during an eight-year period. Their clinical features and treatment responses were contrasted with our experience at Vanderbilt with small...
9.
Grote T, Hainsworth J
Arch Intern Med
. 1987 Dec;
147(12):2212-3.
PMID: 3689074
This report describes a 49-year-old man with hypercalcemia and seminoma. His serum calcitriol (1,25-dihydroxy-vitamin D) level was markedly elevated. Additional endocrine evaluation revealed a normal serum phosphate level, hypercalciuria, and...